



FOR IMMEDIATE RELEASE

**EOM PHARMACEUTICALS APPOINTS BUSINESS VETERAN WAYNE I. DANSON AS
CHIEF FINANCIAL OFFICER AND TREASURER**

MONTVALE, NEW JERSEY – December 17, 2020 -- EOM Pharmaceuticals, a privately held, clinical-stage company, announced today the appointment of business veteran Wayne I. Danson, CPA, as Chief Financial Officer and Treasurer. Mr. Danson will be responsible for leading the Company's financial operations including financial planning and analysis, capital markets, investor relations, accounting, tax and treasury.

Mr. Danson has over 35 years of experience in financial leadership and management experience. He was most recently President and Chief Executive Officer of Danson Partners, LLC, a financial advisory and business consulting firm, specializing in finance, mergers and acquisitions (M&A), business strategy, interim CEO/CFO and turnaround consulting as well as tax services, which he founded in 1999.

Prior to that he was a Partner in large multinational accounting firms and a former Chief Executive Officer and Board Member of one of the largest reverse logistics organizations in the country. He co-founded JDAP Capital Advisors, LLC a private investment management firm and founded Encompass Group Affiliates, Inc., a publicly traded logistics organization that as President, CEO and Chairman of the Board, he grew the business to over \$100 million in sales. Mr. Danson also currently serves as the Chairman of the Board of The chILD Foundation, a national charitable organization dedicated to developing cures for all forms of children's interstitial and diffused lung diseases. Mr. Danson joins an accomplished executive team with a deep legacy in multiple therapeutic areas as well as business success, including:

- **Irach Taraporewala, Ph.D.: EOM Chief Executive Officer and Director**, has multiple accomplishments in drug discovery, development and delivery, formulation, medical devices, radiopharmaceutical and DNA diagnostics, and regulatory affairs. His R&D contributions span several therapeutic areas, including ophthalmology, cancer, inflammation, immunology, endocrine, CNS, infectious disease, malaria and cachexia. Dr. Taraporewala also was the founder, CEO, President, and Board member of OHR Pharmaceuticals, Inc. (NASDAQ-OHRP).
- **Eli Goldberger: EOM's Founder, Chairman and Chief Operating Officer**, a successful entrepreneur, focusing on advancing innovations in pharmaceuticals, women's health, and energy.
- **Shalom Z. Hirschman, M.D.: EOM Co-Founder, Chief Scientific Officer and Medical Director**, served for over 30 years as the Director of Infectious Diseases and Vice Chairman of the Mount Sinai School of Medicine where he was among the first to recognize HIV/AIDS, was a founder of Touro College, and was part of the team that mapped the human genome. Dr. Hirschman also served as CEO, President, and Chief Scientific Officer of Advanced Viral Research Corp.

"Wayne brings a wealth of financial experience and executive leadership to EOM as we prepare to secure additional funding to further invest in clinical trial development for our lead compounds, EOM613 and EOM147, both of which have already been in Phase 2 clinical trials and have demonstrated

improved relevant clinical measures and tolerability,” said Dr. Taraporewala, EOM Chief Executive Officer and Director. “We are fortunate to have someone of Wayne’s caliber join our leadership team and I’m delighted to have him lead our financial strategy and efforts at this important time for our growing company.”

“I am excited to join the experienced and accomplished team at EOM as we embark on developing our innovative therapeutic suite of products designed to improve the health and wellbeing of patients,” said Mr. Danson.

About EOM613

EOM613 is an investigational, first-in-class, dual-acting broad-spectrum immunomodulator designed to provide both an anti-inflammatory effect at the site of cytokine and chemokine overactivity, and a pro-inflammatory effect, when needed. By re-establishing balance, EOM613 may rescue, repair, and restore an immune system that has been confronted by an invading antigen, pathogen, or virus. This dual-acting, broad-spectrum approach may overcome a key limitation of conventional immunomodulators. EOM613 has already demonstrated clinical improvements in various disease states, and immune-related biomarkers and general tolerability across five Phase 2 clinical trials in patients with cachexia associated with AIDS and cancer, and in patients with rheumatoid arthritis. EOM613 is efficiently manufactured from readily available materials. Clinical trials are currently being planned to study EOM613 to treat patients with the most severe effects of COVID-19 and for patients with cancer cachexia, a chemokine-related body-wasting syndrome.

About EOM147

EOM147 is being developed as a proprietary, newly reformulated squalamine-based eye drop, containing a steroid-polyamine conjugate compound with broad-spectrum antimicrobial activity and anti-angiogenic activity. Additional clinical trials in India and Mexico are planned to evaluate EOM147 in the treatment of several retinal diseases that can lead to blindness, including age-related macular degeneration (AMD) and diabetic retinopathies. The novel formulation represents a potential breakthrough because it does not require intraocular injection into the eye and, if approved, would be the first topically administered eye drop to treat retinal diseases.

About EOM Pharmaceuticals

EOM Pharmaceuticals is a privately held, clinical-stage pharmaceutical company with a pipeline of products that have already shown clinical relevance in multiple Phase 2 clinical trials. The Company’s mission is to pursue innovative approaches with novel types of small molecule therapeutics to solve the problems of some of today’s most urgent and unmet medical needs. EOM’s pipeline is built on proprietary innovations designed to rescue, repair, and restore health. These innovations include the development of the first-and-only dual-acting, broad-spectrum immunomodulator EOM613, which has the potential to treat systemic illness due to an intense inflammatory immune reaction, including COVID-19, influenza, and cancer cachexia, and its advanced formulation of EOM147, the first potential topically administered eye drop to treat retinal diseases. Multiple Phase 2 trials suggest EOM613 and EOM147 have improved relevant clinical measures and are well tolerated.

For more information about EOM Pharmaceuticals, please visit www.eompharma.com.

INVESTOR RELATIONS: Eli Goldberger
EOM Pharmaceuticals
elig@eompharma.com

201.351.0605, ext. 2

MEDIA CONTACTS:

Dawn Maniglia
TogoRun
d.maniglia@togorun.com
917.862.5444

###